J Korean Ophthalmol Soc.  2019 Mar;60(3):276-279. 10.3341/jkos.2019.60.3.276.

A Case of Clozapine-induced Corneal and Lenticular Pigmentation

• An JS
• Lee YM
• Kwag JY
• Hyun J
• Choi JS
• Pak KH
• Chung SK

• KMID: 2440456
• DOI: http://doi.org/10.3341/jkos.2019.60.3.276

Abstract

PURPOSE
To report a case of corneal and lenticular pigmentation after prolonged clozapine therapy.
CASE SUMMARY
A 56-year-old male visited our hospital with a progressive decline in vision that affected both eyes. He had a history of schizophrenia. He was being treated with 200 mg clozapine and 1 mg lorazepam daily, and had been treated with clozapine for 5 years. At the first visit, his best-corrected-visual acuity was 20/32 in both eyes. Slit lamp examination of the corneas showed bright, fine, grayish-brown deposits on the endothelium, and on dilation, bilateral central stellate opacity of the anterior portion of the lens capsule was revealed.
CONCLUSIONS
Clozapine may induce corneal and lenticular pigmentation and thus may lead to a decline in vision. Patients on long-term clozapine therapy should be considered for regular ophthalmic review.

Keyword

Clozapine; Corneal pigmentation; Lenticular pigmentation

MeSH Terms

Clozapine
Cornea
Endothelium
Humans
Lorazepam
Male
Middle Aged
Pigmentation*
Schizophrenia
Slit Lamp
Clozapine
Lorazepam

Figure

• 

  Figure 1. Anterior segment photographs showed pigmented deposits on the corneal endothelium. (A) Right eye. (B) Left eye.

• 

  Figure 2. Anterior segment photographs showed pigmented deposits on the lens. (A) Right eye. (B) Left eye.

Reference

References

1. Shahzad S, Suleman MI, Shahab H, et al. Cataract occurrence with antipsychotic drugs. Psychosomatics. 2002; 43:354–9.

2. Kim HS, Choi HJ, Yun YS. Two cases of chlorpromazine-induced corneal and lenticular opacity. J Korean Ophthalmol Soc. 2002; 43:2349–53.

3. Buffaloe WJ, Johnson AW, Sandifer MG Jr. Total dosage of abdominal and ocular opacities. Am J Psychiatry. 1967; 124:250–1.

4. Greiner AC, Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J. 1964; 90:663–5.

5. Lal S, Bloom D, Silver B, et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci. 1993; 18:173–7.

6. Souza VB, Moura Filho FJ, Souza FG, et al. Cataract occurrence in patients treated with antipsychotic drugs. Braz J Psychiatry. 2008; 30:222–6.

7. Choo BJ, Kang YS, Kim TJ, Park JH. A case of cataract after long-term use of clonazepam in a young patient. J Korean Ophthalmol Soc. 2011; 52:1541–4.

8. Borovik AM, Bosch MM, Watson SL. Ocular pigmentation abdominal with clozapine. Med J Aust. 2009; 190:210–1.

9. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005; 10:79–104.

10. Malhotra AK. Pharmacogenomics and schizophrenia: clinical implications. Pharmacogenomics J. 2001; 1:109–14.

11. Lal S, Lal S. Chlorpromazine-induced cutaneous pigmentation abdominal of replacement with clozapine. J Psychiatry Neurosci. 2000; 25:281.

12. Deluise VP, Flynn JT. Asymmetric anterior segment changes abdominal by chlorpromazine. Ann Ophthalmol. 1981; 13:953–5.

13. Razeghinejad MR. Ocular adverse effects of common psychotropic agents: a review. CNS drugs. 2010; 24:977–8.

14. Cohen J, Iuvone PM, Neff NH. Neuroleptic drugs activate tyrosine hydroxylase of retinal amacrine cells. J Pharmacol Exp Ther. 1981; 218:390–4.

15. Alam MS, Praveen Kumar KV. Clozapine-induced cataract in a young female. J Pharmacol Pharmacother. 2016; 7:184–6.